Drugs / LOSATUXIZUMAB VEDOTIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02365662 | Jan 2015 → Mar 2018 | colorectal carcinoma, glioblastoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma +1 | AbbVie | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LOSATUXIZUMAB VEDOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594515 ↗ |
| Known as | ABBV-221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02365662 ↗ |
| Known as | Losatuxizumab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594515 ↗ |
| Known as | Losatuxizumab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594515 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT02365662 ↗ |
| Target | EGFR | “Epidermal growth factor receptor binding agent” CHEMBL4594515 ↗ |